Winslow Evans & Crocker Inc. trimmed its stake in bluebird bio Inc (NASDAQ:BLUE) by 60.5% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 1,500 shares of the biotechnology company’s stock after selling 2,300 shares during the period. Winslow Evans & Crocker Inc.’s holdings in bluebird bio were worth $267,000 as of its most recent filing with the SEC.
Several other institutional investors also recently added to or reduced their stakes in BLUE. Schwab Charles Investment Management Inc. increased its stake in bluebird bio by 51.9% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 266,693 shares of the biotechnology company’s stock worth $36,631,000 after buying an additional 91,161 shares during the period. Tocqueville Asset Management L.P. grew its holdings in bluebird bio by 78.0% during the 3rd quarter. Tocqueville Asset Management L.P. now owns 55,690 shares of the biotechnology company’s stock worth $7,649,000 after acquiring an additional 24,400 shares in the last quarter. Great West Life Assurance Co. Can grew its holdings in bluebird bio by 22.7% during the 3rd quarter. Great West Life Assurance Co. Can now owns 5,531 shares of the biotechnology company’s stock worth $778,000 after acquiring an additional 1,022 shares in the last quarter. Janus Henderson Group PLC acquired a new position in bluebird bio during the 2nd quarter worth approximately $5,252,000. Finally, California Public Employees Retirement System grew its holdings in bluebird bio by 1.5% during the 3rd quarter. California Public Employees Retirement System now owns 86,100 shares of the biotechnology company’s stock worth $11,826,000 after acquiring an additional 1,300 shares in the last quarter.
Shares of bluebird bio Inc (BLUE) traded up $1.00 during trading on Friday, reaching $191.80. 948,445 shares of the company’s stock were exchanged, compared to its average volume of 945,062. The stock has a market cap of $8,790.00, a P/E ratio of -27.36 and a beta of 2.07. bluebird bio Inc has a 52 week low of $73.95 and a 52 week high of $222.03.
Several research analysts have commented on the stock. Morgan Stanley upgraded shares of bluebird bio from an “underweight” rating to an “equal weight” rating in a report on Friday, November 3rd. Leerink Swann cut shares of bluebird bio from an “outperform” rating to a “market perform” rating and boosted their price target for the stock from $162.00 to $194.00 in a report on Thursday, January 25th. Maxim Group set a $170.00 price target on shares of bluebird bio and gave the stock a “buy” rating in a report on Friday, November 17th. Evercore ISI upgraded shares of bluebird bio from an “in-line” rating to an “outperform” rating and set a $102.00 target price for the company in a report on Monday, October 16th. Finally, CIBC initiated coverage on shares of bluebird bio in a report on Thursday, December 21st. They issued a “market perform” rating for the company. Two investment analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $161.45.
In other news, Director Mark Vachon sold 7,000 shares of the stock in a transaction dated Monday, December 11th. The shares were sold at an average price of $216.64, for a total value of $1,516,480.00. Following the completion of the transaction, the director now owns 8,000 shares in the company, valued at approximately $1,733,120. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Nick Leschly sold 5,435 shares of the stock in a transaction dated Friday, January 5th. The shares were sold at an average price of $173.38, for a total transaction of $942,320.30. Following the completion of the transaction, the chief executive officer now owns 171,009 shares of the company’s stock, valued at approximately $29,649,540.42. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 200,280 shares of company stock valued at $37,818,846. 3.90% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: This news story was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://ledgergazette.com/2018/02/12/winslow-evans-crocker-inc-has-267000-stake-in-bluebird-bio-inc-blue.html.
bluebird bio Profile
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.